Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. In 2019, Dr. Johnson received the R.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

NOVEMBER 24, 2019

Future studies will explore psilocybin’s effectiveness as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa, and alcohol use in people with major depression. November 21, 2019.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

The Blunt Truth

AUGUST 13, 2019

In March of 2019, the FDA established a Working Group to determine the possible legislative pathways to regulate CBD. On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 16, 2019

On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Media Releases. Current barriers to patient access to medicinal cannabis in Australia. Fax: +61 2 6277 5829.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

JULY 24, 2019

July 22, 2019. 1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products. RETURN RECEIPT REQUESTED. Joseph Lusardi, President.

CBD 51

CBD Tincture Pets Chronic Pain 51

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JULY 23, 2019

In April 2019 Thurston filed a class action lawsuit in California against Koi CBD, suing it for violations of California State Unfair Competition and Consumer Legal Remedies Laws and the Pennsylvania Unfair Trade Practices and Consumer Protection Law. She lost her job as a result. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. Email: alexander.speiser@eleusisltd.com.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Info

OCTOBER 11, 2019

Cannabis & Dementia: New Study Explores Pot’s Potential for Treatment. In the decades since the medical marijuana movement began in earnest in the 1970s, cannabis has been anecdotally touted as an effective treatment for a variety of illnesses, including those impacting brain function, such as seizures, anxiety and depression.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

Project CBD

FEBRUARY 28, 2023

Sales appear to have peaked in 2019, when natural channel consumers spent more than $90.7 In December 2021, Leafreport, an online CBD resource owned by Empire Media Network, published the results of analyses of 221 CBD products it sent to third-party laboratories for testing. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. Clinical toolkits to help navigate patient assessment and follow-ups. Event details below: Date: Tuesday, September 17th 2019. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Background. 2016 ; Sznitman et al.

Research and Development 52

Research and Development Medicine Access Media 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. Clinical toolkits to help navigate patient assessment and follow-ups. Event details below: Date: Tuesday, September 17th 2019. Time: 9:00AM to 5:00PM.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. But bottlenecks remain to doctors prescribing the controversial treatment.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

SpeedWeed

DECEMBER 28, 2018

Perhaps my new year’s resolution for 2019 will be more rolling, less scrolling! Claiming he’d never tried cannabis before in his life, Dabakis drove to Nevada, bought a cannabis-infused gummy, and then posted a live video feed of himself on social media as he ate the edible. Buzz: Vermont Legalizes Adult-Use Cannabis.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40